DRKS00015267已完成不适用
ong term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARIO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Merck KGaA
- 入组人数
- 1,115
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •Newly initiating oral cladribine or fingolimod according to local label for MS, after the date of oral cladribine launch in the relevant country.
- •- Written informed consent is obtained:
- •- at the date of oral cladribine or fingolimod treatment initiation or, at the latest, 24 weeks after oral cladribine or fingolimod treatment initiation in all countries for which primary data is used.
- •- in those countries where secondary data collection is used and require an informed consent.
排除标准
- •- Received fingolimod prior to initiating oral cladribine;
- •- Received oral cladribine prior to initiating fingolimod.
研究者
相似试验
招募中
4 期
ong term prospective observational cohort study on the safety and efficacy of abatacept subcutaneus in the daily clinical practice of rheumatoid arthritisInflammatory rheumatic disease10023213NL-OMON39013Jan van Breemen Instituut100
招募中
4 期
ong term prospective observational cohort study of the safety and efficacy of golimumab in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profileinflammatory rheumatic disease1000381610023213NL-OMON36406Jan van Breemen Instituut200
招募中
4 期
ong term prospective observational cohort study of the safety and efficacy of certolizumab pegol in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profileinflammatory rheumatic disease1000381610023213NL-OMON36770Jan van Breemen Instituut200
招募中
不适用
A longitudinal prospective, observational, cohort study in lactating mothers and their newborns to further unravel the complexity of human milkNL-OMON53220utricia Research120
尚未招募
不适用
Comparison of suspected or negative cases with confirmed cases of COVID-19 at Max HospitalCTRI/2020/04/024772Max Healthcare A Unit of Devki Devi Foundation